Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fluxion signs distribution agreement with Bucher Biotec
Bucher will handle sales and service in Switzerland of Fluxion’s BioFlux research tools for live cell image analysis in drug discovery. The Fluxion BioFlux 200 system is ideal
Bucher will handle sales and service in Switzerland of Fluxion’s BioFlux research tools for live cell image analysis in drug discovery. The Fluxion BioFlux 200 system is ideal
Bristol-Myers Squibb initiated a cash tender offer on May 29, 2008, to purchase all outstanding common stock of Kosan for $5.50 per share. The tender offer expired at
In its submission to the Commission’s ongoing pharmaceutical sector inquiry, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has assured the Commission that the perceived decline in
The National Health Service (NHS) has long had a policy that patients who spend their own money for expensive drugs that aren’t reimbursed by the government automatically become
According to projections made by a national commission set up in 1979 to monitor social spending (CCSS), the whole social security system in France is likely to sustain
A report from the Center for Responsive Politics has also revealed that the Pharmaceutical Research and Manufacturers of America (PhRMA) spent $3.61 million on political lobbying during the
Genetic testing of MDR1 variation has become an increasingly important part of many drug discovery and development efforts. The particular variant covered by the patent issued to Epidauros,
According to the agreement, International Medical Systems (IMS) will have the exclusive right to sell the Lapex 2000 LipoLaser in the following countries during the first phase of
The underwriters have a 30-day option to purchase up to an additional 825,000 shares of common stock. Sequenom expects the net proceeds from the offering to be used
Famotidine Injection is indicated for the short term treatment of duodenal and gastric ulcers and gastroesophageal reflux disease. Famotidine Injection is therapeutically equivalent to the brand product Pepcid